3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
23
Neoplasm Metastasis
10
Stomach Neoplasms
5
Colorectal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Esophageal Neoplasms
3
Brain Neoplasms
3
Adenocarcinoma
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Neoplasms
2
Meningeal Carcinomatosis
2
HER2-positive Breast Cancer
2
Breast Cancer With Brain Metastasis
2
Unresectable Locally Recurrent Breast Cancer
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neoplasm, Residual
1
Inflammatory Breast Neoplasms
1
HER2-negative Breast Cancer
1
HER2-mutant Non-Small Cell Lung Cancer
1
HER2-low Hormone Receptor Positive Breast Cancer
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Gastric Adenocarcinoma
1
Colonic Neoplasms
1
Carcinoma
1
Interventions
blinatumomab
9
Cyclophosphamide
7
Rituximab
6
Lenalidomide
6
Dexamethasone
5
Azacitidine
5
venetoclax
4
fludarabine
4
Cytarabine
4
fludarabine phosphate
3
Maintenance
3
Busulfan
3
tislelizumab
2
thymoglobulin
2
pembrolizumab
2
obinutuzumab
2
daratumumab
2
Whole-Body Irradiation
2
N,N-dicyclohexyl-isoborneol-10-sulfonamide
2
Methotrexate
2
Melphalan
2
Immunotherapy
2
Imatinib Mesylate
2
Drug Therapy
2
Docetaxel
2
Decitabine
2
Clofarabine
2
Cladribine
2
Carboplatin
2
Calcium Dobesilate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasm, Residual
×
trastuzumab deruxtecan
×
Clear all
NCT05965479
2024-11-12
DECIPHER
University of Southampton
Phase 2
Recruiting
25 enrolled